Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Drug development in oncology commonly exploits the tools of molecular biology to gain therapeutic benefit through reprograming of cellular responses. In immuno‐oncology (IO) the aim is to direct the patient’s own immune system to fight cancer. After remarkable successes of antibodies targeting PD1/PD‐L1 and CTLA4 receptors in targeted patient populations, the focus of further development has shifted toward combination therapies. However, the current drug‐development approach of exploiting a vast number of possible combination targets and dosing regimens has proven to be challenging and is arguably inefficient. In particular, the unprecedented number of clinical trials testing different combinations may no longer be sustainable by the population of available patients. Further development in IO requires a step change in selection and validation of candidate therapies to decrease development attrition rate and limit the number of clinical trials. Quantitative systems pharmacology (QSP) proposes to tackle this challenge through mechanistic modeling and simulation. Compounds’ pharmacokinetics, target binding, and mechanisms of action as well as existing knowledge on the underlying tumor and immune system biology are described by quantitative, dynamic models aiming to predict clinical results for novel combinations. Here, we review the current QSP approaches, the legacy of mathematical models available to quantitative clinical pharmacologists describing interaction between tumor and immune system, and the recent development of IO QSP platform models. We argue that QSP and virtual patients can be integrated as a new tool in existing IO drug development approaches to increase the efficiency and effectiveness of the search for novel combination therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“Interestingly, it has been shown that TGF-β attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells.(36) Hence, for immune excluded phenotypes, the inhibition of TGF-β enhances the efficacy of immune-checkpoint blockade therapies, which is observed in preclinical studies of murine breast an…”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Universally Sloppy Parameter Sensitivities in Systems Biology Models
Gutenkunst, R. N., Waterfall, J. J., Casey, F. P., Brown, K. S., Myers, C. R., & Sethna, J. P. (2007) · PLoS Computational Biology · doi:10.1371/journal.pcbi.0030189 · Cited by 1,261
Shebley, M., Sandhu, P., Emami Riedmaier, A., Jamei, M., Narayanan, R., Patel, A., Peters, S. A., Reddy, V. P., Zheng, M., de Zwart, L., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1013 · Cited by 395 · cited 2×
“9 The key feature of PBPK models that enable this important application is REVIEW the incorporation of the detailed mechanistic knowledge and in vitro assays available before a trial is conducted (i.e., binding and processing of compounds by drug metabolizing enzyme).”
BackgroundKnudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan?
Vicini, P., & van der Graaf, P. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.40 · Cited by 108
A Six‐Stage Workflow for Robust Application of Systems Pharmacology
Gadkar, K., Kirouac, D., Mager, D., van der Graaf, P., & Ramanujan, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12071 · Cited by 93 · cited 1×
“73 Another advantage of a large-scale mechanistic model is that although its creation may be slow, the application is very fast.”
BackgroundFriedrich, C. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12056 · Cited by 87 · cited 1×
“75 Although precise guidelines have not yet been agreed by the community and regulators, authors appreciate that qualification should be done with consideration of the risk of following model predictions in a particular context of use.”
Background
Cited by
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01188-4 · Cited by 122
“By generating a virtual patient population with similar characteristics to the target patient cohort, mechanistic models can compare different therapy combinations and potential biomarkers for patient strati fi cation 9 .”
MethodSelf-citationGoryanin, I., Goryanin, I., & Demin, O. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104448 · Cited by 21
Assessing the performance of QSP models: biology as the driver for validation
Singh, F. A., Afzal, N., Smithline, S. J., & Thalhauser, C. J. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-023-09871-x · Cited by 15
Wang, H., Arulraj, T., Ippolito, A., & Popel, A. S. (2024) · Handbook of Experimental Pharmacology · doi:10.1007/164_2024_735 · Cited by 6
Self-citation
Metadata
- Authors
- Chelliah, V., Lazarou, G., Bhatnagar, S., Gibbs, J. P., Nijsen, M., Ray, A., Stoll, B., Thompson, R. A., Gulati, A., Soukharev, S., Yamada, A., Weddell, J., Sayama, H., Oishi, M., Wittemer‐Rump, S., Patel, C., Niederalt, C., Burghaus, R., Scheerans, C., Lippert, J., Kabilan, S., Kareva, I., Belousova, N., Rolfe, A., Zutshi, A., Chenel, M., Venezia, F., Fouliard, S., Oberwittler, H., Scholer‐Dahirel, A., Lelievre, H., Bottino, D., Collins, S. C., Nguyen, H. Q., Wang, H., Yoneyama, T., Zhu, A. Z. X., van der Graaf, P. H., & Kierzek, A. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2020-08-14
- Volume
- 109
- Issue
- 3
- Pages
- 605-618
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W3042239416
- Cited by
- 76
- References
- 11
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm. https://app.cochat.ai/papers/10.1002/cpt.1987
- The paper
- Chelliah, V., Lazarou, G., Bhatnagar, S., Gibbs, J. P., Nijsen, M., Ray, A., Stoll, B., Thompson, R. A., Gulati, A., Soukharev, S., Yamada, A., Weddell, J., Sayama, H., Oishi, M., Wittemer‐Rump, S., Patel, C., Niederalt, C., Burghaus, R., Scheerans, C., . . . Kierzek, A. M. (2021). Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.1987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.